Clinical trials: Treatment Failure
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA).
- Trial name
- NCT00065260
- Testing
- Campath-1H, r-ATG, CsA
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Heart Failure
Vitamin D Supplementation for Treatment of Heart Failure
The central objective of this proposal is to establish that vitamin D supplementation in heart failure patients with low vitamin D levels will have improved outcomes compared to placebo.
- Trial name
- DELIGHTFUL (NCT01230307)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan
Heart Failure
Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients
The purpose of the study is to evaluate the benefit of interventricular (V-V) delay optimization in reducing the non-responder rate in patients with cardiac resynchronization defibrillator (CRT-D) devices.
- Trial name
- NCT00187200
- Testing
- Simultaneous VV Pacing, Sequential VV Pacing
- Where
- United States
- Volunteers
- 816 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as…
- Trial name
- NCT01439009
- Testing
- Tolvaptan
- Where
- 8 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Fanconi Anemia, Myelodysplastic Syndrome (MDS)
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
The goal of this study is to see if the study therapy can decrease the chemotherapy-related side effects while maximizing the effectiveness of disease control.
- Conditions
- Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
- Trial name
- NCT03600909
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Renal Failure
Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?
Intravenous iron therapy is common and effective, with few side effects. Two formulations are used, venofer or iron sucrose and ferrlecit, or ferric gluconate.
- Trial name
- NCT02420119
- Testing
- non interventional
- Where
- Israel
- Volunteers
- 53 people
- Sponsor
- Frieda Wolf
Metastatic Colorectal Cancer (mCRC)
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and Lonsurf) no longer have treatment options available while maintaining a good performance status which…
- Trial name
- NEXT-REGIRI (NCT03829462)
- Testing
- Regorafenib, Irinotecan
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Anemia, Diamond-Blackfan
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag
Background: Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work.
- Trial name
- NCT04269889
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiomyopathy
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
The purpose of this trial or study is to determine if cardiac resynchronization therapy (CRT) can be a benefit to people who have impaired heart function due to past treatment with chemotherapy and/or chest radiation.
- Trial name
- MADIT-CHIC (NCT02164721)
- Testing
- Three-lead CRT-D (Defibrillator)
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Myelodysplastic Syndromes
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in…
- Trial name
- NCT02721875
- Testing
- Volasertib, Azacitidine
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
The purpose of this post approval study is to conduct a prospective, multicenter evaluation of the procedural and clinical outcomes of subjects that are treated with the commercially available Medtronic Resolute Integrity…
- Trial name
- RI-US (NCT01638507)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Medtronic Vascular
Systolic Heart Failure, Cardiac Resynchronization Therapy
ECG for Programming in CRT
Patients with heart failure and left bundle branch block benefit from Cardiac Resynchronization Therapy (CRT) that delivers pacing from right ventricle (RV) and left ventricle (LV) synchronously, resulting in electrical…
- Conditions
- Systolic Heart Failure, Cardiac Resynchronization Therapy, Electrocardiography
- Trial name
- EPIC (NCT03936608)
- Testing
- Programming individualized RV-LV pacing offset to optimize ECG, Nominally programming CRT device without RV-LV offset
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Aplastic Anemia
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy.
- Trial name
- NCT02404025
- Testing
- Eltrombopag, Rabbit ATG, CsA
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
The primary objective of the study is to determine the efficacy of natalizumab (Tysabri, BG00002) in participants with relapsing forms of multiple sclerosis (MS) who have failed Gilenya or BRACET (Betaseron, Rebif, Avonex…
- Trial name
- ESCALATE (NCT02241785)
- Testing
- natalizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Anemia
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling…
- Trial name
- NCT00286182
- Testing
- Erythropoietin alpha
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mathew S. Maurer
Lung Cancer
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced…
- Trial name
- NCT01000025
- Testing
- PF-00299804
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 720 people
- Sponsor
- NCIC Clinical Trials Group
Congestive Heart Failure
Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Patients who present to clinic or in the outpatient setting with worsening heart failure represent a unique opportunity for novel approaches to decongestion (removing fluid) that may more rapidly improve fluid status and symptoms…
- Trial name
- TROUPER (NCT02476409)
- Testing
- tolvaptan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital